چکیده (انگلیسی):

Tocilizumab, A new anti-rheumatic drug developed by Hoffmann–
La Roche and Chugai under the trade name Actemra.
It was recently approved by the U.S. Food and Drug Administration
(US FDA) on January 2010 for the treatment of moderate
to severe rheumatoid arthritis. It is a humanized
monoclonal antibody targeted against the interleukin-6 receptor
(IL-6R) causing immunosuppression and mainly used for
the treatment of rheumatoid arthritis (Haghighi and Safari,
2008). Interleukin 6 is a cytokine that has a main role in immune
response and is implicated in the pathogenesis of many
diseases, such as autoimmune diseases, multiple myeloma
and prostate cancer